Zepbound vs Wegovy: How the Two Weight-Loss Drugs Compare

This article compares the two products — approvals, evidence, cost, and access. If you want the underlying pharmacology, our guide to tirzepatide vs semaglutide covers how the molecules differ and why.

Both belong to the incretin class, but they aren't variations of the same thing.

Wegovy (semaglutide) activates the GLP-1 receptor. That slows gastric emptying and acts on appetite regulation in the brain.

Zepbound (tirzepatide) activates the GLP-1 receptor *and* the GIP receptor. The dual mechanism is the main structural argument for why it tends to produce larger reductions.

That's the substance of the mechanical difference. Everything that follows is what it means in practice.

Here's where most comparison articles get sloppy, and it's worth doing properly.

The two drugs were largely studied in separate trials, against placebo, in populations that weren't identical. Semaglutide's pivotal obesity trial reported mean weight reduction of about 15% over 68 weeks (Wilding et al., 2021). Tirzepatide's reported up to roughly 21% at the highest dose over 72 weeks (Jastreboff et al., 2022).

Putting those two numbers side by side is a cross-trial comparison, which is not the same as a head-to-head result. Different participants, different durations, different protocols.

The rigorous way to compare treatments that weren't directly tested against each other is a network meta-analysis, which statistically links them through their shared comparators. Two recent ones are relevant:

• A living systematic review and network meta-analysis conducted for the American College of Physicians assessed the benefits and harms of pharmacologic obesity treatments (Damen et al., 2026).
• A systematic review and network meta-analysis of GLP-1 receptor and dual agonists for weight loss (Vienghirun et al., 2026).

The consistent finding across this body of work is that tirzepatide-based treatment generally ranks ahead of semaglutide for average weight reduction. That's a real and reasonably well-supported conclusion.

Two caveats that matter more than the ranking:

Averages hide enormous individual variation. A drug that performs better on average is not the drug that will perform better for you. Some people respond strongly to semaglutide and poorly to tirzepatide.

Tolerability decides outcomes too. The medication you can actually stay on beats the one that theoretically works better. Both carry a substantial gastrointestinal burden.

This is the part that decides the answer for whole groups of people, and it gets buried everywhere else.

Zepbound is approved for obstructive sleep apnea in adults with obesity, in addition to chronic weight management. If you have moderate-to-severe OSA, that's a meaningful distinction — it can change what a physician recommends and what insurance will cover.

Wegovy is approved for reducing the risk of cardiovascular events in certain adults with established cardiovascular disease and overweight or obesity, alongside chronic weight management. If you have cardiovascular disease, that indication may matter more than a few percentage points of average weight loss.

So the honest framing isn't "which is better." It's: do you have a condition that one of them is specifically approved to treat? If yes, that usually settles it. If no, the decision moves to tolerability, cost, and access.

Wegovy also comes in an oral form, which matters if injections are a genuine obstacle for you.

Both share the same profile, because both act on the same core pathway. The most common effects are gastrointestinal — nausea, diarrhea, constipation, vomiting, and reduced appetite — worst when starting and after each dose increase, easing at a stable dose.

Both carry a boxed warning for thyroid C-cell tumours based on rodent studies, and neither should be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Both carry risks of pancreatitis, gallbladder problems, and severe dehydration from prolonged GI symptoms.

Some evidence suggests tirzepatide produces gastrointestinal effects somewhat more often, which would be unsurprising given the greater average effect — but this shouldn't drive a decision on its own. Our guide to tirzepatide side effects covers the full picture, and it applies to Zepbound directly.

For most people this is the actual deciding factor, and it's where the comparison stops being about pharmacology.

Both brand products carry list prices well over a thousand dollars a month. Almost nobody pays that, but what you *do* pay varies enormously.

Insurance coverage is the biggest single variable, and many plans exclude weight-loss medications as a category. Where a plan does cover one, it often covers only one — which means your formulary may decide this for you regardless of which you'd prefer.

Both manufacturers run savings programs and direct cash-pay options, and both have changed terms repeatedly. Check current terms directly rather than trusting any article, including this one.

The approvals interact with coverage. If you have obstructive sleep apnea or established cardiovascular disease, the relevant approval may be what unlocks coverage — another reason the indications matter more than the effectiveness ranking.

Something both of the top-ranking comparisons skip, and it surprises people more than any difference between the drugs.

Neither one starts at its full dose. Both are escalated gradually over months, stepping up at intervals so the body can adapt. That means:

• The dose that produced the trial results is not the dose you begin on. The headline figures come from people who reached and stayed at higher doses over a year or more.
• Every step up tends to bring a fresh wave of side effects, which then settles. People frequently interpret that as the drug getting worse when it's the ramp repeating.
• Judging either medication in the first month is judging the titration, not the treatment.
• Escalation pace is adjustable. If each step is rough, that's a real conversation with your prescriber rather than a reason to switch drugs or quit.

This matters for the comparison because people often abandon one medication during escalation and conclude the other would have been better. Frequently the difference was the pace, not the molecule.

For most people this is the actual outcome, so it deserves more than a sentence.

Denial is common and it isn't the end of the process. Plans that exclude weight-loss medications as a category will refuse both. Plans that cover them often require prior authorisation, documented BMI thresholds, or evidence of prior attempts at weight management.

Routes worth knowing:

• Prior authorisation. Frequently the requirement rather than a rejection. Your prescriber's office usually handles it, and specific documentation is often what unlocks it.
• Appeal. Denials are appealable and appeals do succeed, particularly where a covered indication applies — which is where Zepbound's sleep apnea approval or Wegovy's cardiovascular indication can change the outcome.
• A different product on your formulary. Sometimes the answer isn't either of these two.
• Manufacturer savings and cash-pay programmes, which have expanded considerably and narrowed the gap with compounded options.
• Compounded treatment, with the trade-offs described below.

The order matters. People often jump straight from a denial to cash-pay without attempting prior authorisation or an appeal, and that skips the two routes that would have cost them nothing.

Every article ranking for this question compares the two brand products and stops there. That leaves out what a large number of people actually end up doing.

Both molecules are available in compounded form. Compounded semaglutide and compounded tirzepatide are prepared by compounding pharmacies against a prescription, and cost is the main reason people use them.

The trade-offs are real and worth stating plainly:

• Compounded medications are not FDA-approved. They haven't been through the review or the trials described above.
• They are not the same products as Wegovy or Zepbound, and formulations vary — many include additional ingredients such as B12 or preservatives that the brand products don't contain.
• Quality depends entirely on the compounding pharmacy, which makes the pharmacy, its licensing, and its testing the thing to evaluate.
• The approvals above don't transfer. A compounded tirzepatide product is not approved for sleep apnea; compounded semaglutide is not approved for cardiovascular risk reduction. Those indications belong to the brand products that earned them.

Protocol MD sells compounded semaglutide and compounded tirzepatide. We're stating that here rather than at the bottom, because it means you should read this section with that in mind. If you can access or afford Wegovy or Zepbound, those carry an evidence base and a set of approvals that compounded versions do not.

A reasonable way to think about it:

• You have obstructive sleep apnea → Zepbound is approved for it.
• You have established cardiovascular disease → Wegovy's indication may matter more than the weight-loss ranking.
• Your insurance covers one and not the other → that's usually your answer, and arguing with a formulary rarely works.
• Injections are a genuine obstacle → Wegovy's oral form is worth discussing.
• Neither is covered and cost is the barrier → savings programs, manufacturer cash-pay options, and compounded treatment are the routes, in roughly that order of evidence strength.
• You tried one and couldn't tolerate it → switching is reasonable, but they share a mechanism, so discuss dose and pace with your prescriber before assuming the class is out.

• Given my health history, is one of these specifically indicated for me?
• Which does my insurance actually cover, and what's the process if it's denied?
• If cost is the barrier, what are my realistic options?
• I couldn't tolerate one — is switching likely to help, or is it the class?
• What should we monitor once I start?

Protocol MD's semaglutide and tirzepatide are physician-prescribed and compounded. Compounded medications are not FDA-approved and are not the same as the brand-name products. A US-licensed physician reviews your history, decides whether treatment is appropriate, and manages it over time.

We don't sell Wegovy or Zepbound, and if one of them is the right answer for you — because of an indication you have or coverage you can access — that's the better-evidenced route and we'd rather say so than pretend otherwise.

If you're considering treatment, it starts with a physician evaluation. Our comparison of the underlying molecules covers the pharmacology in more depth.

Zepbound is tirzepatide, Wegovy is semaglutide, and on average tirzepatide has produced more weight loss in the evidence — a conclusion supported by network meta-analyses rather than just by putting two trial numbers next to each other. But that ranking is the least useful thing about the comparison for most individual people. What usually decides it is whether you have a condition one of them is specifically approved to treat, which one your insurance will actually pay for, and which one you can tolerate well enough to stay on. Compounded versions of both molecules exist and are what many people end up using on cost grounds, with the trade-off that they aren't FDA-approved and don't carry those approvals. Work through the indications and the coverage first — the effectiveness question usually turns out to be the easy part.